The PennZone

  • Home
  • Non-profit
  • Books
  • Health
  • Marketing
  • Entertainment
  • Sports
  • Business
  • Legal

Penn Dental Medicine Study Shows How HIV Infection Impacts Brain's White Matter
The PennZone/10132115

Trending...
  • Bountiful Bowl Aims to Raise $50,000 to Support Meals on Wheels of the Greater Lehigh Valley
  • New Research Spotlight, Expanding TUSC2 Science & Strategic Development Milestones Put Gene Therapy Innovation into Focus for Genprex (NAS DAQ: GNPX)
  • WebDrafter Welcomes Dreamwork Exteriors as a New Marketing Client
PHILADELPHIA, June 18, 2021 /PRNewswire/ -- It's long been known that people living with HIV experience a loss of white matter in their brains. As opposed to gray matter, which is composed of the cell bodies of neurons, white matter is made up of cells that produce myelin, a fatty substance that coats neurons, offering protection and helping them transmit signals efficiently. A reduction in white matter is associated with motor and cognitive impairment.

Earlier work by a team from Penn Dental Medicine and Children's Hospital of Philadelphia (CHOP) found that antiretroviral therapy (ART)—the lifesaving drugs that many with HIV use daily—can reduce white matter, but it wasn't clear how the virus itself contributed to this loss.

In a new study using both human and rodent cells, the team has determined how HIV prevents the myelin-making brain cells called oligodendrocytes from maturing, reducing white matter production. When the researchers applied a compound blocking to this process, the cells were once again able to mature. The work appears in the journal Glia.

More on The PennZone
  • Logicraft Launches FuelDeck™, AI That Turns Aviation Fuel Tickets Into One Traceable Ledger
  • Inaugural OC Tech Week Draws 3,000 From 12 Countries, Sends Finalist to $1M Startup World Cup
  • Award-Winning American Hotelier Opens Art-Filled Luxury Cottage in Norfolk, England
  • K2 Global / Ozi Amanat Named Among Top 100 AI Venture Capitalists in 2026
  • Dr. Latorial Faison Appointed Poet Laureate of Virginia

"Even when people with HIV have their disease well-controlled by antiretrovirals, they still have the virus present in their bodies, so this study came out of our interest in understanding how HIV infection itself affects white matter," says Kelly Jordan-Sciutto, professor at Penn Dental Medicine and the study's co-senior author. "By understanding those mechanisms, we can take the next step to protect people with HIV from these impacts."

Jordan-Sciutto and Judith Grinspan, CHOP research scientist and Professor of Neurology at Penn Medicine, have been collaborating to elucidate how ART and HIV affect the brain. Their previous work on antiretrovirals had shown that commonly used drugs disrupted the function of oligodendrocytes, reducing myelin formation.

More on The PennZone
  • AdLeverage Brings Golf Simulator Contest and Home Services Marketing Expertise to Service World Expo 2026
  • Cleveland Factory Worker Seeks Funding for AI-Readable Archive Exploring Advanced AI Restraint and Human Survival
  • Ten Ten Ten Announces Maximizing Quality Performance, a Value-Based Care Implementation Guide
  • Hunter's Garage Teams Up With The Small Batch for a Free Thanksgiving Meal
  • TradeJARnal Launches Innovative Trading Journal to Help Stock and Options Traders Build Discipline and Smarter Trading Habits

In the current study, they aimed to isolate the effect of HIV on this process by looking at human macrophages, one of the major cell types that HIV infects.

Ultimately, the researchers want to discern the effects of the virus from the drugs used to treat it in order to better evaluate the risks of each.

"When we put people on ART, it's important to understand the implications," says Jordan-Sciutto. "Antiretrovirals may prevent the establishment of a viral reservoir in the central nervous system, which would be wonderful, but we also know some drugs have unintended consequences, which may include altering white matter." Read more on the study >>

Contact: Beth Adams, [email protected]

SOURCE Penn Dental Medicine

Related Links

http://www.dental.upenn.edu
Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • AthleteMerch.com Surpasses 100,000 Custom Items Delivered to Fans Nationwide
  • MoMojo Records Signs Gary Nicholson
  • Steve Weclew is Appointed by STS Capital Partners as Managing Director
  • Communities In Schools of Eastern Pennsylvania Honors United Way and Local Leaders
  • New Finnish Affiliate Site Ilmaiskierrokset.com Puts Wager-Free Spins in the Spotlight
  • Major FDA Victory; Preservative-Free Ketamine Approved Ahead of November 10 Goal Date as Commercial Launch Opportunity Comes Into Focus for NRx Pharma
  • Veterans Day Breakfast Celebration in Valley Forge to Honor America's Military Heroes
  • Best Black Friday 2026 Deals on Lightweight Foldable Electric Wheelchairs – Save Up to 60%
  • Immerse Yourself in the Historic Tochigi Autumn Festival, Celebrated Every Two Years Since 1874
  • Resident Inspect Expands Virtual Property Inspections With AppFolio and Rentvine Integrations
  • Unlocking the Next Phase of Growth with New AI Innovations; Targeting 2027 as Breakeven; Revenue Momentum Accelerates: ZenaTech (N A S D A Q: ZENA)
  • Dr. Marilyn Pendelton Releases The Grief Reset to Address Grief Beyond Death
  • AeroNet Deploys netElastic vBNG and CGNAT with Tarana Wireless to Deliver Scalable, Fiber-Class Broadband Across Puerto Rico
  • New Atlas Maps the 38 States Behind Every Conversation
  • Atlanta Company Launches Free, Ad-Free, Nonpartisan Voter Planning App for All 50 States Ahead of the Nov. 3 Election
  • Pastor Carlton L. Aiken Sr. Celebrates 55 Years with "Sermonic Selections"
  • J. Wes Seeks Jazz Musicians, Vocalists and Bands for Philadelphia Live Music Event
  • NECP Promotes Chertova to Senior Business Analyst
  • Security Industry Veteran Anthony Rumore Launches AegisLead to Help Security Companies Find Business and Manage Growth
  • Charlie Shaw and Patrick Carragher win SEO Agency of the Year 2026

Popular on PennZone

  • SMACK Fighting Championships Announces Influencer Fight Night at Harrah's Philadelphia - 205
  • ASSIST Software Wins Volkswagen Challenge for Automated Quality Inspection - 101
  • New Children's Picture Book "Tippy Tay" Explores the Dangers of Peer Pressure and the Importance of
  • New Children's Picture Book "Adam's Apple" Celebrates Childhood Curiosity and the Funny Misundersta
  • RAS AP Consulting Issues National Compliance Alert and Launches Q4 2026 AP Readiness Program Ahead of IRS FIRE → IRIS Cutover
  • Free Senior Housing Webinar Helps Families Plan for Aging Before a Crisis Forces Difficult Decisions
  • LS2 Partners with Angels Of Dirt's "Next Chapter Racer" Series Celebrating Women and Girls in Motorsports
  • What Mold Remediation Costs in Gettysburg, PA: 2026 Price Ranges by Job Type
  • Pittsburgh Digital Marketing Agency Moves to Babcock Boulevard in the North Hills
  • Creole101 Launches Multilingual Dictionary App with 50,000+ Entries, Vocabulary Games and Haitian Cultural Resources

Similar on PennZone

  • FDA Approval; Major Milestone for Preservative-Free Ketamine Ahead of FDA Goal Date for Treatment of Suicidal Depression by NRx Pharmaceuticals, Inc
  • Building a Technology Powerhouse-From AI Drones and Global Acquisitions to Defense, Enterprise Software and the Future of Autonomous Operations $ZENA
  • K2 Global / Ozi Amanat Named Among Top 100 AI Venture Capitalists in 2026
  • Pursant Founder Mark Herbick Joins STS Capital Partners as CEO
  • Tampa Web Design Launches New Website for Entrepreneur and Capital Markets Advisor Martin Sumichrast
  • UK Financial Ltd. Announces Maya Preferred PRA as First Fully Verified Asset on MAYA CHAIN; Chainlink Proof of Reserve Integration Planned for Network
  • RAS AP Consulting Advances 1099 Education and Readiness Initiative Through IFOL Training and Finance Technology Showcase
  • Steve Weclew is Appointed by STS Capital Partners as Managing Director
  • Major FDA Victory; Preservative-Free Ketamine Approved Ahead of November 10 Goal Date as Commercial Launch Opportunity Comes Into Focus for NRx Pharma
  • Unlocking the Next Phase of Growth with New AI Innovations; Targeting 2027 as Breakeven; Revenue Momentum Accelerates: ZenaTech (N A S D A Q: ZENA)
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us